Key facts
- Aegle Therapeutics’s last known valuation is $18.0M (Jan 2020).
- It has raised $13.6M across 1 recorded rounds; the latest was Later Stage VC ($4.6M) in Mar 2026.
- Notable investors include Springboard Enterprises, United States Department of War, DEFTA Partners, Deepwork Capital, New World Angels — 7 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Aegle Therapeutics
Funding rounds
1 roundsAbout Aegle Therapeutics
Developer of regenerative medicines designed for treating rare dermatological disorders. The company's medicines utilize extracellular vesicle (EV) therapy derived from mesenchymal stem cells to deliver biomolecular payloads, offering regenerative, immunomodulatory, and anti-inflammatory properties, enabling patients with conditions such as dystrophic epidermolysis bullosa to access cell-free treatments that promote healing, reduce scarring, and improve overall skin health through advanced therapeutic applications.
- Sector
- Healthcare
- HQ
- Woburn, MA, United States
- Founded
- 2013
- Employees
- 5
- Website
- aegletherapeutics.com/
- Ownership
- Privately Held (backing)
Aegle Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aegle Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aegle Therapeutics in its N-PORT filings yet. We sweep new filings monthly.